title: [P21 expression in renal interstitial fibrosis and regulative effect of enalapril].
abstract: OBJECTIVE
  To investigate the expression of P21 in renal interstitial fibrosis rats and the effect of enalapril on it.
  
  
  METHODS
  Sprague Dawley rats were randomly divided into 3 groups: a sham operation group,a unilateral urethral obstruction group, and an enalapril treatment group. The expression of P21 in renal tubular epithelial cells on the process was detected by immunohistochemistry at different time spots (7, 14, 21 d after UUO, sham-surgery or enalapril treatment). The expression of p21 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  
  
  RESULTS
  Seven days after the surgery, significant differences were found in P21 expression between UUO and SOR renal tubular cells. With degree of interstitial fibrosis aggravating, P21 expression increased. Enalapril can inhibit its expression.
  
  
  CONCLUSIONS
  In the kidney of UUO rats, P21 expression increased and enalapril possessed significant inhibitory effects on the procedure. P21 may participate in the pathogenesis of renal tubule-interstitial fibrosis.
authors.affiliation: Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Xiao
authors.forename: Li-jian
authors.initials: LJ
authors.lastname: Tao
authors.forename: Tang
authors.initials: T
authors.lastname: Damu
authors.forename: Ou
authors.initials: O
authors.lastname: Jin
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Zhou
authors.forename: Ming
authors.initials: M
authors.lastname: Shen
authors.forename: Jing
authors.initials: J
authors.lastname: Hu
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.forename: Wang-bin
authors.initials: WB
authors.lastname: Ning
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D009400:Nephrosclerosis / Q000188:drug therapy* / Q000378:metabolism*; D016283:Proto-Oncogene Proteins p21(ras) / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014517:Ureteral Obstruction / Q000150:complications
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D012333:RNA, Messenger; D004656:Enalapril; D016283:Proto-Oncogene Proteins p21(ras)